









Markets
/
Stocks
/
nasdaq-crmd
/

CorMedix Inc

CRMD

7.690USD

+0.340+4.63%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

602.50MMarket Cap

3.24P/E TTM



CorMedix Inc

7.690

+0.340+4.63%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of CorMedix Inc

Currency: USD Updated: 2026-02-06

Key Insights

CorMedix Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 58 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 16.14.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

CorMedix Inc's Score

Industry at a Glance

Industry Ranking

58 / 159

Overall Ranking

168 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

CorMedix Inc Highlights

StrengthsRisks

CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 66363.08% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 43.47M.

Overvalued

The company’s latest PE is 3.24, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 43.86M shares, increasing 0.02% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 6.95K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 2.50.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

16.143

Target Price

+105.90%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of CorMedix Inc is 8.34, ranking 73 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 104.28M, representing a year-over-year increase of 810.22%, while its net profit experienced a year-over-year increase of 4009.63%.

Score

Industry at a Glance

Previous score

8.34

Change



Financials

6.70

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.34

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.66

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

CorMedix Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of CorMedix Inc is 6.70, ranking 117 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 3.24, which is 1840.65% below the recent high of 62.87 and 1396.38% above the recent low of -41.99.

Score

Industry at a Glance

Previous score

6.70

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 58/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of CorMedix Inc is 8.29, ranking 48 out of 159 in the Pharmaceuticals industry. The average price target is 20.00, with a high of 22.00 and a low of 14.00.

Score

Industry at a Glance

Previous score

8.29

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

16.143

Target Price

+105.90%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

CorMedix Inc

CRMD

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of CorMedix Inc is 7.39, ranking 61 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 8.63 and the support level at 6.65, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.02

Change

0.37

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.286

Neutral

RSI(14)

40.915

Neutral

STOCH(KDJ)(9,3,3)

33.856

Sell

ATR(14)

0.436

High Vlolatility

CCI(14)

-10.373

Neutral

Williams %R

42.424

Buy

TRIX(12,20)

-1.196

Sell

StochRSI(14)

62.124

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

7.834

Sell

MA10

7.821

Sell

MA20

7.492

Buy

MA50

9.715

Sell

MA100

10.371

Sell

MA200

11.328

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of CorMedix Inc is 5.00, ranking 73 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 55.93%, representing a quarter-over-quarter decrease of 0.71%. The largest institutional shareholder is The Vanguard, holding a total of 4.48M shares, representing 5.69% of shares outstanding, with 6.19% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

5.04M

+5.18%

Deep Track Capital LP

4.96M

+891.10%

Abdalkader (Shaibatalhamd Aymen)

4.65M

The Vanguard Group, Inc.

Star Investors

3.96M

-8.07%

Marshall Wace LLP

3.47M

+34.63%

Deerfield Management Company, L.P.

3.32M

State Street Investment Management (US)

1.84M

+14.61%

Geode Capital Management, L.L.C.

1.81M

+13.37%

Citadel Advisors LLC

1.72M

+0.17%

Alyeska Investment Group, L.P.

1.26M

+68.40%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of CorMedix Inc is 5.19, ranking 74 out of 159 in the Pharmaceuticals industry. The company's beta value is 1.30. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.